Cantor Fitzgerald Brokers Lower Earnings Estimates for JSPR

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Jasper Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings per share of ($4.52) for the year, down from their previous forecast of ($4.17). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

A number of other analysts have also recently issued reports on JSPR. Oppenheimer reduced their price objective on Jasper Therapeutics from $80.00 to $65.00 and set an “outperform” rating for the company in a research report on Thursday. UBS Group reduced their price objective on Jasper Therapeutics from $38.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $62.22.

Jasper Therapeutics Trading Up 1.2%

JSPR opened at $4.93 on Friday. The stock has a market cap of $74.06 million, a price-to-earnings ratio of -1.04 and a beta of 2.74. Jasper Therapeutics has a 1 year low of $3.13 and a 1 year high of $26.84. The stock has a fifty day moving average price of $4.60 and a 200 day moving average price of $10.93.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.24).

Hedge Funds Weigh In On Jasper Therapeutics

Institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its holdings in Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after buying an additional 3,828 shares in the last quarter. EntryPoint Capital LLC bought a new position in shares of Jasper Therapeutics in the fourth quarter worth about $223,000. Tema Etfs LLC bought a new position in shares of Jasper Therapeutics in the fourth quarter worth about $266,000. Rhumbline Advisers increased its stake in shares of Jasper Therapeutics by 12.6% in the fourth quarter. Rhumbline Advisers now owns 14,761 shares of the company’s stock worth $316,000 after purchasing an additional 1,652 shares during the period. Finally, Barclays PLC increased its stake in shares of Jasper Therapeutics by 320.7% in the third quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after purchasing an additional 12,308 shares during the period. 79.85% of the stock is currently owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.